Detail Tag

ID Term Name
85 QoL
86 Cognition
87 Co-morbidities
88 Adherence
89 Treatment resistance
90 Diagnosis
91 Stigma
92 Pharmacology
93 Biomarkers
94 Technology
95 Comorbidity
96 Treatment
97 Research
98 Nonclinical
99 Preclinical
100 Symptoms
101 Aetiology
102 Relapse
103 Response
104 Carer
105 Patient management
106 Physical health
108 DSM5
109 DSM-5
112 Pathogenesis
113 Pathology
116 Remission
117 Compliance
118 Suicide
119 Prevention
120 Prognosis
121 Genetics
150 MDD
151 Neurocognition
152 Psychology
153 Psychosis
154 Weight-gain
155 First-episode
156 Antipsychotics
157 Lifestyle
158 Quality of Life
159 First episode
160 Comic
161 Disease management
162 Epidemiology
163 Screening
164 Burden
165 Course of disease
166 Functional outcome
167 Residual symptoms
168 Switching treatment
169 Placebo effect
170 Metabolic risks
171 Mania64
172 Questionnaires
173 Causes
174 Mania with depressive symptoms
175 Bipolar I management
176 Cognitive impairment
177 Agitation
179 Irritability
180 Top of the Polls
181 Blog post
182 Bipolar I treatment
183 Mania
184 Opinion piece
191 SNC
192 Various
197 Endophenotype
198 Review
201 Management
202 Management. Diagnosis
203 Course of the disease
204 Physical function
205 Social function
206 Latest thinking
207 Events
208 Cognitive dysfunction
209 THINC-it tool
210 Impaired function
211 Inadequate response
212 Working
213 Daily life
215 Depression
216 Cognitive deficit
217 Function
218 Work
219 Under-managed
220 Depression; Comorbidity; Substance use disorders; Dopamine
221 First episode psychosis
222 Post-Traumatic Stress Disorder (PTSD); Dementia; Alzheimer’s disease; PET imaging
223 Depression; Stress; Resilience; HPA axis
224 Depression; Inflammation; Immune markers; Cytokines; Biomarkers; Suicide
225 Depression; Bipolar disorder
226 Dual disorders; Depression; Schizophrenia; Bipolar disorder; Substance use
227 Schizophrenia; Caregiver; Employment; Productivity
231 Depression; Cognitive deficit; Function; Work; Under-managed
232 Culture
233 Society
234 Socio-cultural
235 Research; Pharmacology;
236 psychiatry; young scientists; researchers; medical education
237 psychiatry; researchers; medical education
238 neuropsychopharmacology; medical education; CINP; psychiatry
239 schizophrenia; imaging; dopaminergic circuitry; psychiatry
240 schizophrenia; dopamine; imaging; deficits; dysfunction
241 computational neuroscience; imaging biomarkers; autism; schizophrenia; depression
242 MedEd
244 Alzheimer; Demência;
245 Variedades
246 Diagnóstico
247 suicídio
248 prevenção
249 Quadrinhos
250 Vários
253 Risk
254 Assessment
255 Reseach
259 Psychopharmacology
260 Neuroimaging
262 Depresión; Estres; Resilencia; HPA axis
263 Cognición
264 Tecnología
265 Investigación
266 Salud física
267 Riesgo metabólico
268 Sintomas residuales
269 TDM
270 Neurocognición
271 Psicología
272 Síntomas
273 Depresión; Inflamación; Marcadores inmunológicos; Biomarcadores; Suicidio; Citocinas
274 Depresión
275 Transtorno Bipolar
276 Schizophrenia
277 Full Functional Recovery
278 Functioning
280 etiología
281 Epidemiología
282 Genética
283 manejo
284 patología
285 tratamiento
286 trastorno bipolar
287 formación médica
288 formación
289 actualización
290 enfermedad mental
291 psiquiatría
292 neurología
293 Vieta
294 Bipolar Disorder
295 psychiatry
296 Risks
300 aetioogy
301 Comorbidities
302 Sleep
304 Summary of Recent Paper
305 Europeandepressionday
306 Thethincittool
307 Thincittool
308 Eziologia
309 Prevenzione
310 Rischio
311 Depressione
312 Schizofrenia
313 Salute Mentale
314 Preclinica
315 Sonno
316 Trattamento
317 Fattori di Rischio
318 SOPSI
320 Caregivers
322 Scientific Association
323 Age of onset
324 Sexual abuse
325 Genetic loading
326 ICD-10
327 Debate
328 The concept of schizophrenia
329 Split mind
330 Curso de la enfermedad
331 Primer episodio
332 Edad de inicio
333 Abuso sexual
334 Carga genética
335 Access to treatments
336 social cognition
337 Disorganized schizophrenia
338 Mentalizing deficits
339 Negative symptoms
340 Voice from the floor
341 Inflammation
342 Pro-inflammitory cytokines
343 Default mode network
344 Mixed states
345 ICD-11
346 MDS – 200 Years of PD
347 Computational neuroscience
348 Imaging biomarkers
349 Autism
350 Dopamine
351 Imaging
352 Deficits
353 Dysfunction
354 Dopaminergic circuitry
355 Researchers
356 Medical education
357 Young scientists
358 European Commission
359 MRI-based predictive models
360 PRONIA
361 TRIMAGE
362 IMAGEMEND
363 OPTiMiSE
364 Personalized medicine
365 Autism spectrum disorders
366 Neuronale correlates
367 Brain organoids
368 Altered connectivity
369 Dual disorders
370 Substance use
371 Stress
372 Resilience
373 HPA axis
374 Caregiver
375 Employment
376 Productivity
377 Immune markers
378 Cytokines
379 Post-Traumatic Stress Disorder (PTSD)
380 Dementia
381 Alzheimer’s disease
382 PET imaging
383 Substance use disorders
385 Negative symptoms of schizophrenia
386 Neuroimagining
387 Motivation-related symptoms
388 deficit in expression
389 Diagnonsis
390 Schizophrenia subtypes
391 Deficit schizophrenia
392 Treatment resistant schizophrenia
393 Novel Markers
394 Tool to predict outcome
395 Gender identity
396 Gender dysporia
397 Gender reassignment
398 CdV
399 Prevención
400 Aderencia
402 Length of stay
403 10 days
404 Readmission
405 Starting treatment
406 Long-term
407 Movie Comment
412 guideline
413 APA
414 Registry
415 One year after
416 Madrid 2017
437 Endofenotipo
438 CIE-10
439 Red neuronal por defecto
440 Cognición social
441 Estados mixtos
442 CIE-11
444 Interview
445 Diagnotic challenges
446 Mixed episodes
447 Medical comorbidity
448 Cognitive symptoms
449 Predictors of response
450 Prof Andrea Fagiolini
451 Neurology
452 Unmet Needs
454 workplace
455 world mental health day
456 mental health
457 brain
460 Schizophrenia; Remission; Treatment
461 Clinical
462 Memory and cognitive disorders
463 Functional impairment
464 Biological markers
465 Diagnoses and classification
466 Methodology
467 Functional improvement
468 Long acting injectable antipsychotics (LAIs)
469 Clinical outcomes
470 Determinants of outcome
471 Patient preference for outcomes
472 Stated preference methodology
473 Patient-tailored management of schizophrenia
474 Doctor’s perspective
475 Neurotoxicity
476 Continuous treatment
477 Diagnoses & classification
478 RDoC
479 Transdiagnostic research
481 Congreso Nacional de Psiquiatría Legal
482 Satellite Symposium
483 Remission
484 E-Health Tool
485 Treatment Selection in Schizpophrenia
486 Treatment resistant schizophrenia (TRS)
487 Treatment algorithms for TRS
488 Treatment option for TRS
489 Insomnia
490 Animal models
491 Growth factors
492 Biomakers
493 psychoneuroendocrinology
494 neurosteroids
495 depression stress
496 Symptoms
497 Scientific Exchange
498 Top paper session
499 Highlights
500 GPC
501 glial progenitor cell
502 HDAC
503 histone deacetylase
505 Schizophrenia and Functioning
506 D2 Partial Antagonist Antipsychotics
507 Pharmacology of D2 Partial Agonists
508 Role of Partial D2 Agonist in Schizophrenia
509 D2 Partial Agonist and Functioning
510 clinical Study Results and Functioning
511 Course of disease; patient management; prevention; ECNP patient session
512 Congnición
513 puesto de trabajo
514 día mundial de la salud mental
515 salud mental
516 cerebro
517 Trastorno por consumo de alcohol
518 Abordaje integral
519 entrevista motivacional
521 molecular genetics
522 calcium
523 aethiology
525 Esquizofrenia
526 Simposio
527 Congreso nacional de psiquiatría 2017
528 Alzheimer
529 depression: clinical
530 Early treatment
531 Measurement-based care
532 Confidence in treatment
533 GABA
534 Schizophrenia basic
538 aidant/travailleur social
539 patient care
540 during illness
541 premier épisode
542 recherche
543 QdV
544 Prise en charge de la maladie ; Prise en charge du patient
545 Symptoms
546 Evaluation
547 Évolution de la maladie
548 Gestion thérapeutique
549 Prise en charge des patients
550 Risques
551 Processing
552 Qualité de vie
553 Étiologie
554 Réponse inadéquate
555 Biomarcadores Patología
557 FAST
558 Escala de evaluación funcional
559 HAM-D
560 Escala de depresión de Hamilton
561 Calidad de vida
562 epidémiologie
563 revue
564 génétiques
565 Aethiologie
566 pathologie
567 préclinique
568 entrevista
569 expertos
570 psiquiatras
571 trastornobipolar
572 paciente
573 metabolico
574 depresion. mensaje
575 1802PIM03
576 diagnostic
577 fardeau
578 rechute
580 disease management
582 santé physique
583 schizophrénie
584 imagerie
585 trouble déficitaire
586 dysfonctionnement
587 질병의 관리
588 환자 관리
589 예방
590 약리학
591 항정신병약
592 병리학
593 역학
594 전임상
595 동반질환
596 신체 건강
597 관해(remission)
598 인지기능
599 삶의 질(QoL)
600 증상
601 병인
602 유전학
603 리뷰
604 치료
605 사회적 부담
606 질병의 경과
607 dormir
608 평가
609 연구
610 바이오마커
611 순응도
612 진단
613 자살
615 Neural networking
616 Insight
617 THINC-it
618 Real-world evidence
619 CBT
620 Executive function
621 Recovery
622 Real-worlds evidence
623 MADRS
624 mechanism of action
626 Classification
627 Meta-analyses
628 Individualized therapy
629 treatent
630 Polypharmacy
631 Antypsychotics
632 Adverse events
633 Cognitive remediation
634 Metacognition
635 Ultra-high risk
636 Early Intervention
637 ARMS
638 Early detection
640 Illness
641 Phenotype
642 Experience
643 Interpretation
644 Functional recovery
645 Policy
646 Stakeholder involvement
647 Sintomas cognitivos
648 EPA
649 Telepsychiatry
650 Education
651 Peer support
652 Resource
653 Pathophysiology
654 Pharmacogenetics
655 Stratification
656 Neuroanatomy
658 Patient managmeent
659 Nutrition
660 Multidomain intervention
661 Diet
662 Amyloid
663 Hypometabolism
664 Astrocytosis
665 Neuroradiology
666 Target
667 Tau
668 Microglial inflammation
669 Time course
670 Microbiota
671 LPS
672 Escherichia coli
673 Microbiome
674 Gram-negative bacteria
675 Bacteroides fragilis
676 Publich Health
677 Cardiovascular Disease
678 obesity
679 Centiloid
680 Trial
681 Diagnosis Genetics
682 Prelinical
683 GBA
684 GCase
685 UPSIT
686 DAT imaging
687 Patient
688 Early interventions
689 Funcitoning
690 Network
691 New definition
692 Mental illness
693 cogniiton
694 public health
695 at-risk children
696 family history
697 Disclosure
698 Symptom overlap
699 MRI
700 Computing
701 Wearable technology
702 Big Data
703 Machine learning
704 Cluster
705 Genotype
706 Stress response
707 PTSD
708 Person-centered approach
709 VAST-D
710 Treatment-resistant Schizophrenia
711 TRS
712 Care recipient
713 Consequences
714 Health
715 stigmate
716 Διαχείριση ασθενούς
717 Υποτροπή
718 Διαχείριση της νόσου
719 Πρώτο επεισόδιο
720 Θεραπεία
721 Φορτίο
722 Πορεία της νόσου
723 예후
724 Αξιολόγηση
725 Γνωσιακή λειτουργία
726 Ύφεση
727 Διάγνωση
728 Έλεγχος
729 Συμπτώματα
730 esquizofrenia resistente al tratamiento
731 CATIE
732 intervencion temprana
733 esquizofrenia resistente
734 Αντιψυχωτικά
735 psychose
736 pharmacologie
737 personnels soignants et aidants
738 biomarqueurs
739 스크리닝
740 THINC®
742 Λειτουργικότητα στη Σχιζοφρένεια
743 video
745 Cardiovascular Disease
746 obesity
747 Network
748 New definition
749 Mental illness
750 Telepsychiatry
751 Education
752 Peer support
753 Resource
754 treatent
755 Polypharmacy
756 Antypsychotics
757 Adverse events
758 THINC-it
759 Real-world evidence
760 CBT
761 Executive function
762 Pathophysiology
763 Pharmacogenetics
764 Stratification
765 Neuroanatomy
766 Neural networking
767 Insight
768 Meta-analyses
769 Individualized therapy
770 Cognitive remediation
771 Metacognition
772 Ultra-high risk
774 Centiloid
775 Amyloid
776 Trial
777 Patient managmeent
778 Nutrition
779 Multidomain intervention
780 Diet
781 Microbiota
782 LPS
783 Escherichia coli
784 Microbiome
785 Gram-negative bacteria
786 Bacteroides fragilis
787 Hypometabolism
788 Astrocytosis
789 Neuroradiology
790 Target
791 Tau
792 Microglial inflammation
793 Time course
794 Diagnosis Genetics
795 Prelinical
796 GBA
797 GCase
798 UPSIT
799 DAT imaging
800 Publich Health
801 Early Intervention
802 ARMS
803 Early detection
804 Patient
805 Early interventions
806 Funcitoning
808 Policy
809 Stakeholder involvement
810 Illness
811 Phenotype
812 Experience
813 Interpretation
814 Functional recovery
815 cogniiton
816 public health
817 at-risk children
818 family history
819 Disclosure
820 Assess ment
821 Cognitive behavioral therapy
822 Rating scales
823 Microcircuits
824 Macrocircuits
826 Classification
827 Recovery
828 Real-worlds evidence
829 MADRS
830 HAM-D
831 mechanism of action
832 Genotype
833 Stress response
834 PTSD
835 Person-centered approach
836 VAST-D
837 Symptom overlap
838 MRI
839 Computing
840 Wearable technology
841 Big Data
842 Machine learning
843 Cluster
844 Social media
845 campaign
846 Anti-stigma
847 Immunotherapy
848 Dose
849 Disease-modifying therapy
850 PK/PD modeling
851 Collaborative care
852 Care manager
853 ISER
854 QALY
855 Treatment-resistant Schizophrenia
856 TRS
857 Care recipient
858 Consequences
859 Health
860 Therapeutic strategy
861 Positive symptoms
863 Environment
864 Urban
865 Nature
866 Brain activity
867 Public--Private partnership
868 Phenotyping
869 Biotype
870 Brain connectivity
871 LAI
872 Antipsychotic
873 Hospitalization
874 Efficacy
875 Tolerability
876 Weight
877 Side effect
878 Παραμονή στη θεραπεία
879 Comobidity
880 Substance abuse
881 OCD
882 OnTrackNY
883 PEPPNET
884 RAISE
885 FEP
886 NAVIGATE
887 COMPASS
888 STEP-ED
889 MOST
890 Metanalysis
891 Trajectory analysis
892 Prodrome
893 Attenuated Psychosis Syndrome
894 Synaptic pruning
895 Hippocampus
896 CA1
897 Field studies
898 WHO
899 PET
900 DBS
901 Gait
902 Deep brain stimulation
903 Coulse of Disease
904 Formulation
905 Alpha-synuclein
906 Levodopa
907 -course of disease
908 Trajectory
909 Development
910 Neurogenesis
911 22q11.2
912 Therapeutic target
913 COMT
914 Tbx1
915 Variant
916 Algorithm
917 Longitudinal database
918 Observational database
919 Identification
920 Epigenetics
921 Outcome
922 Variables
923 Treatment response
924 Predictor
925 Editorial Board Meeting
926 Observance
927 pronostic
928 résultats sur le fonctionnement
930 Probiotics
931 EBM
932 Neuronal circuitry
933 Burden of disease
935 Drug targets
936 Risk factor
937 Weight gain
938 Metabolic disease
939 Tratment
940 Real-world
941 Clinical practice
942 Safety
943 Partial agonist
944 D2 receptor
945 Brain Shrinkage
946 Outcomes
947 Patholoy
948 22q11.2 microdeletion
949 mechanism
950 translation
951 Therapeutic targets
952 Behavior
953 아포지단백E
954 Late life depression
955 Neuroinflammation
956 Motivation
957 Cognitive Remediation Therapy
958 Social functioning
959 Prescribing
961 Normative modeling
962 Connectivity
963 Antidepressant
964 Prediction
965 Brain circuit
967 우울증
968 인지증상
969 당뇨병
970 Network dysfunction
971 EEG
972 Magneto-encephalography
973 Research networks
974 Drug development
975 MFS
976 양극성장애
977 아동기
978 해마
979 vie quotidienne
980 réponse
981 Psychosocial
982 Aging
983 Statistics
984 Wearable devises
987 John FP Bridges
988 대한불안의학회 춘계학술대회
989 주요우울장애(MDD)
990 대한불안의학회
992 대한신경정신의학회 춘계학술대회
993 콜레스테롤
994 스타틴
995 AAIC 2018
997 간병인
998 Manejo de la enfermedad
999 Manejo del paciente
1000 Respuesta Parcial
1001 Farmacología
1002 Dopamina
1003 Modelado normativo
1004 Conectividad
1005 Red
1006 Antidepresivo
1007 Predicción
1008 Respuesta
1009 Circuito cerebral
1010 guias terapeuticas
1011 CINP 2017
1012 analisis
1013 evidencia clínica
1014 Disease mangement
1015 Cognitive assessment
1016 Multimodal interventions
1017 Medical education and training
1018 Student mental health
1019 Adherance
1020 Diabetes
1021 Dopamine D2 receptor agonists
1022 fonctionnement
1023 주요우울장애
1024 영상 유전학
1025 Shared decision-making
1026 Goal setting
1027 tools
1028 DSST
1029 PDQ
1030 Patient perspective
1031 Treatment goals
1032 Treatment choices
1033 Gut-brain axis
1034 5HT2
1035 Supersensitivity
1036 Antagonist
1037 Real-world data
1038 Effectiveness
1039 Workplace performance
1040 functional recovery
1041 Patient's goals
1042 stakeholder
1043 Lived experience
1044 Precision medicine
1045 Targeted therapy
1046 Therapeutic drug monitoring
1047 Life goals
1048 Costs
1049 Duration of untreated psychosis
1050 RAISE-ETP
1051 Subtyping
1052 Digital technology
1053 Monitoring
1054 OFF
1055 Freezing
1056 Exeercise
1057 영상유전학
1061 OPUS panel
1062 DUP
1063 Treatment delay
1064 Online intervention
1065 Teatment
1066 Patient goals
1067 Patient expectations
1068 Brain imaging
1069 Research Domain Criteria
1070 Amyloid-beta
1071 Apolipoprotein E
1072 Blood:brain barrier
1073 comorbidité
1074 neuroimagerie
1075 Glutamate
1076 NMDA receptor antagonists
1077 Neuroprogression
1078 Neuroprotection
1079 Severity
1080 Psychotherapy
1081 Diseasemanagement
1082 Stigma resistance
1083 Internalized stigma
1084 Long-acting injectable antipsychotic
1085 Clinical trials
1086 Early Alzheimer's disease
1087 Artificial intelligence
1088 Neurodevelopment
1089 Connectome
1090 Creativity
1091 Polyunsaturated fatty acids
1093 Transition to psychosis
1094 Cost
1095 Survey
1096 Awareness
1097 Neurobiology
1098 Burde
1099 Subtypes
1100 Disease heterogeneity
1101 Assessment. Cognition. Disease management. Patient management. Remission. Symptoms. Treatment. Function.
1102 ECNP
1103 funcionanildad
1104 sistema dopaminergico
1105 tolerabilidad
1106 Sexual functioning
1107 Mixed features
1108 DSM-5 MADRS
1109 PHQ-9
1110 YMRS
1111 Science
1112 synapse
1113 Circuit
1114 Striatum
1115 Reverse emotional valence
1116 Disease managemet
1117 Long-acting injectable antipsychotic (LAI)
1118 Oral antipsychotic (OAP)
1119 Real world
1120 Mirror study
1121 Genetic
1122 NICE
1123 Clinical trial
1124 Early dialogues
1125 Evidence generation plans
1126 HTA
1127 Health ecnomics
1128 Patient-centered research
1129 Advocacy
1130 Patient engagement
1131 Healthcare
1132 삶의 질
1134 consenso
1135 recuperacion funcional
1136 documento
1137 abordaje compartido de la depresion
1138 Anxiété
1139 réseau par défaut
1140 Adeherance
1141 Functional MRI
1142 Networks
1143 Striatal functional recovery
1144 Striatal Connectivity index
1145 Hospital stay
1146 Mindfulness
1147 NYC START
1148 Fidelity scale
1149 Funding
1150 Service delivery
1151 Critical period
1152 Basket cell
1153 Parvalbumin
1154 Perineural net
1155 CHR
1156 SHARP study
1157 LIA
1158 DaT scan
1159 Differential diagnosis
1160 Early diagnosis
1161 Sequencing
1162 WGS
1163 WES
1164 ethics
1165 Whole genome sequencing
1166 Whole exome sequencing
1167 IRB
1168 Enhancer elements
1170 Prodromal
1171 Motor symptoms
1172 Non-motor symptoms
1173 Drug repurposing
1174 Biometric monitoring
1175 Electronic health records
1176 neuropathology
1177 Protein
1178 Misdiagnosis
1179 Fluid biomarker
1180 Solid biomarker
1181 치매
1182 알츠하이머
1183 Έρευνα
1184 psicosis
1185 perspectiva del paciente
1186 tratamiento de la esquizofrenia
1188 Disease managemnet
1189 Patient mangement
1190 evaluacion sintomatica
1191 efectos adversos
1192 enfoque de la depresión
1193 avances en depresión
1194 GDPR
1195 Digital health
1196 Healthcare delivery
1197 Real-world data
1198 Training
1199 Patient-relevant outcomes
1200 PROs
1201 Industry
1202 Label
1203 RCTs
1204 Cost-effectiveness
1205 Subgroup
1206 Funcitonal symptoms
1207 Clinical care
1208 Patient-focused drug development
1209 Patient-centered clinical care
1210 Podcast
1211 funcionalidad
1212 CIE 11
1213 antipsicóticos
1214 재발(relapse)
1215 neurotixina
1216 neurotixicidad
1218 atencion primaria
1219 resistance au traitement
1220 thinc it tool
1223 Bipolar
1224 기술
1226 Philip Gorwood
1227 trastorno depresivo mayor
1228 Πρόληψη
1229 Επίδραση του εικονικού σκευάσματος
1230 Trial designs
1231 Amyloid beta
1232 Neurofilament light chain
1233 Lewy body disease LBD
1234 Multiple system atrophy MSA
1235 PPMI
1236 Alpha synuclein
1237 Neurogranin
1238 Enteric nervous system
1239 Lewy bodies
1240 Glia
1241 Microglia
1242 Innate immune system
1243 Symptom networks
1244 Neural plasticity
1245 Patient experts
1246 Partnership
1247 Neuropathophysiology
1248 Digital phenotyping
1249 Scales
1250 Disease severity
1251 Personalized treatment
1252 Virtual reality
1253 Avatars
1254 Complement cascade
1255 Immunity
1256 Innate immunity
1257 Long acting injectable
1258 social
1259 UHR
1260 HiTOP
1261 SPINS
1262 biomarcadores
1263 neuroimagen
1264 engoque holístico
1265 Pain
1266 Opiates
1267 fMRI
1268 DTI
1269 Meta-analysis
1270 Motivational interviews
1271 App
1272 Registries
1273 Glutamine
1274 Αιτιολογία
1275 Γενετική
1276 Consensus
1277 Staging
1278 Exome sequencing
1279 TBAR
1280 Folate
1281 Gut microbiota
1282 Psychobiotic
1283 Prebiotic
1286 Health economics
1287 Migration
1288 Risk factors
1289 Psychoeducation
1290 Asesoramiento
1291 síntomas negativos
1292 Primeros episodios
1293 outils d'e-santé
1294 sélection de traitement de la schizophrénie
1295 Guidelines
1296 Pro-inflammatory mediators
1297 Interleukin
1298 TNF
1299 pre-clínico
1300 ADHD
1301 inattention
1302 hyperactivity
1303 impulsivity
1304 Absenteeism
1305 Presenteeism
1306 Employee
1307 Ultra high risk
1309 Neurocognitive training
1310 BNSS
1311 SNS
1312 SSRI
1313 PDGF
1314 Dopaminergic
1315 Glutamatergic
1316 IL-17
1317 CRP
1320 Amygdala
1321 Prefrontal cortex modulation
1322 Behaviour
1323 Adherencia
1324 Asesoriamiento
1325 ILP
1326 Incidencia
1327 carga
1328 Side-effects
1329 Measure-cased care
1330 PANSS-6
1331 Coordinated Specialty Care
1332 Life trajectory
1333 Φροντιστής
1334 Cognitive
1335 prise en charge
1336 résistance
1338 BDNF
1339 Gestão de doenças
1340 Gestão de pacientes
1341 Remissão
1342 Tratamento
1343 Cognição
1344 Curso de uma doença
1345 Saúde física
1346 Reincidência
1347 Resposta inadequada
1348 Etiologia Pesquisa Genética
1349 Pesquisa
1350 Primeiro episódio
1351 Imagiologia
1353 symptômes négatifs
1355 Functional movement disorders
1357 징후
1358 Essential tremor
1359 Aeitology
1360 Stakeholders
1361 Collaboration
1362 Innovation
1363 Sleep hygiene
1364 Aβ42 oligomer
1365 Amyloid-β
1366 Astrocyte
1367 Neurotoxin
1374 depot medication
1375 long acting injectables  
1376 Diseasase management
1377 Patient-centricity
1378 Rational prescribing
1379 Nomenclature
1380 Anhedonia
1381 Intervention
1382 High risk groups
1383 Apathy
1384 Long acting injectables
1385 Treatments
1386 Sympotoms
1387 Pharamacology
1388 Emotional blunting
1389 Agression
1390 Oxytocin
1391 Vasopressin
1392 Caffeine
1393 Adverse early life experiences
1394 Depression; Inflammation
1396 Alphasynuclein
1397 Disease modifying treatment
1398 Prodomal PD
1399 Congress highlights
1400 Neuropsychiatric symptoms
1401 Algorithms
1402 Sex difference
1403 Telemedicine
1404 Movement disorders
1405 Tele-education
1406 Telerehabilitation
1407 Telemetry
1408 Tics and Tourette syndrome
1409 Chatbot
1410 AI
1411 Adverse effects
1412 Pharmacogenomics
1413 Polygenic risk score
1414 Genome-wide association studies
1415 Melatonin
1416 Circadian rhythm
1417 Blue-depleted light
1418 Duration of hospitalization
1419 Neuroradiologist
1420 Resilience building
1421 Media
1422 Biomarker
1423 Research Pharmacology
1424 Metabolic
1425 LAC
1426 Lactate
1427 Trait qualifiers
1428 Epidemiology Physical health
1429 Mortality
1430 Mortality Gap
1431 Harm reduction
1432 Functional
1433 SNRI
1434 Treatment.
1435 Hypomania
1436 apps
1437 Transdiagnostic
1438 Social withdrawal
1442 First episode psychosis.
1443 Cognitive bias
1444 Neural circuits
1445 Onset of effect
1446 Disease treatment
1447 focalización
1448 p value
1449 Effect size
1450 Number needed to treat (NNT)
1451 Number needed to harm (NNH)
1452 Benefit-risk assessment
1453 치료의 내성
1454 불충분한 반응
1455 September 7 - 10
1456 2019 Copenhagen
1457 Denmark
1458 Venue: Bella Center Copenhagen
1459 Address: Center Blvd. 5
1460 2300 København
1464 불안
1465
1466 CSF
1467 Alzheimer’s continuum
1468 Health disparities
1469 Life course
1470 Prevelance
1471 DCTClock
1472 Integrated Cognitive Assessment (ICA)
1473 Asymptomatic AD
1474 Plaque-induced genes (PIGS)
1475 APOE
1476 TREM2
1477 Motivational interviewing
1478 Neurotransmitters
1479 Serotonin transporter gene promoter region
1480 Cormorbidity
1481 Borderline personality disorder
1482 Substance use disorder
1483 Differantial Diagnosis
1494 Translational research
1495 초조
1496 조증
1497 Lundbeck symposiumet 2019
1498 Lundbeck symposiumet
1499 Διαταραχή Χρήσης Αλκοόλ
1500 Lundbecksymposiet 2019
1501 Lundbecksymposiet
1502 Functional gastrointestinal disorders
1503 Functional dyspepsia
1504 Irritable bowel syndrome
1505 정신병 에피소드
1506 Придържане
1507 Оценка
1508 Лечение на пациента
1509 Когниция
1510 Рецидив
1511 Отговор
1512 Възстановяване
1513 Реални доказателства
1514 Механизъм на действие
1515 Лечение на болестта
1516 Първи епизод
1517 Лечение
1518 Невротоксичност
1519 Продължително лечение
1520 Коморбидност
1521 Скрининг
1522 Качество на живот
1523 Депресия
1524 Когнитивен дефицит
1525 Функциониране
1526 Работа
1527 Недолекуван
1528 Научни изследвания
1529 Upoštevanje zdravljenja
1530 Vodenje bolnikov
1531 Preference bolnikov pri doseganju izida
1532 Metodologija navajanja preferenc
1533 Vodenje shizofrenije po meri bolnikov
1534 Ocenjevanje
1535 Obvladovanje bolezni
1536 Simptomi
1537 Zdravljenje
1538 Nevralno mreženje
1539 Funkcioniranje
1540 Vpogled
1541 Depresija
1542 Kognitivni primanjkljaj
1543 Delo
1544 Nezadostno upravljanje
1545 Shizofrenija in funkcioniranje
1546 Neizpolnjene potrebe
1547 Antipsihotiki
1548 Antipsihotiki delnega
1549 D2 antagonista
1550 Farmakologija delnega agonizma
1551 D2
1552 Vloga delnega agonizma za D2 pri shizofreniji
1553 Delni agonist D2 in funkcioniranje
1554 Rezultati kliničnih študij in funkcioniranje
1555 Kognicija
1556 Kakovost življenja
1557 Znanstvene izmenjave
1558 Komorbidnost
1559 Presejanje
1560 Relaps
1561 Prva epizoda
1562 Nevrotoksičnost
1563 Dolgotrajno zdravljenje
1564 Ocena
1565 Raziskave
1568 Enfermedad de Parkinson
1569 Sexual Dysfunction
1570 Antidepressant induced sexual dysfunction
1571 PLISSIT model
1572 Asistencia
1573 Neurobiologia
1574 Estudio SHARP
1575 Hospitalización
1576 experto
1577 circuitos neuronales
1578 Resistente al tratamiento
1579 Investigación translacional
1580 Baune
1581 Bridges
1583 Aetiología
1584 Envejecimiento
1585 KOL
1586 enfermedad cardiovascular
1587 neuroinflamación
1588 beta amiloide
1589 Comorbilidad
1590 Curso de vida
1591 Prevalencia
1592 Astrocitos
1593 revisión
1594 Patogénesis
1595 Neurotoxina
1596 cuerpos Lewi
1597 Alfa-sinucleina
1598 respuesta inadecuada
1599 síntomas motores
1600 síntomas no motores
1601 Tratamientos
1602 Modificación del tratamiento
1603 Titulares de congreso
1604 síntomas neuropsiquiátricos
1605 Tremor esencial
1606 biomar
1607 Cuerpos de Lewi
1608 trastornos afectivos
1609 TLP
1610 episodios mixtos
1611 ICHD-3
1612 Aura
1613 Headache
1614 Neuropeptides
1615 Calcitonin gene-related peptide
1616 CGRP
1617 Disability
1618 Triggers
1619 Monthly migraine days (MMD)
1620 Pituitary adenylate cyclase-activating polypeptide
1621 PACAP Chronic migraine
1622 Evolution
1623 Natural selection
1624 Pregnancy
1625 Infant colic
1626 Postdrome
1627 PACAP
1628 Neuromodulation
1629 Monoclonal antibody
1630 Ictal migraine
1631 Trigeminovascular system
1632 Patient education
1633 Approach to treatment
1634 Improving outcomes
1635 New treatment
1636 CGRP antagonists
1637 Cronic migraine
1638 Episodic migraine
1639 Hard-to-treat migraine
1640 Resources
1642 Treatment compliance
1643 Treatment tolerance
1644 Disease features
1645 Disease classification
1648 trastorno límite de la personalidad
1649 travail
1650 위약 효과
1653 Hyposmia
1654 Prodome
1655 Στίγμα
1656 Ποιότητα Ζωής
1657 α-synuclein
1658 Disease modifying therapy
1659 COVID-19
1660 Pandemic
1661 Quarantine
1662 Social isolation
1663 CBTpsychosis
1664 CBTp
1665 Acceptance and Commitment therapy (ACT)
1666 Individualized Metacognitive Training (MCT+)
1667 Brain training
1668 Physical exercise
1669 Active-play video games
1670 Auditory hallucinations
1671 Cardiorespiratory fitness
1672 Reduce Trial
1673 HAMLETT
1674 TAILOR
1675 RADAR
1676 Taper
1677 Discontinuation
1678 Dose reduction
1680 Procjena
1681 Istraživanje
1682 Kvaliteta života
1683 Znanstvena razmjena
1684 Komorbiditet
1685 Probir
1686 Liječenje
1687 Pridržavanje terapije
1688 Pristup bolesniku
1689 Remisija
1690 Odgovor
1691 Oporavak
1692 Dokazi iz stvarnog života
1693 Mehanizam djelovanja
1694 Pristup bolesti
1695 Neuralno umrežavanje
1696 Uvid
1697 Neurotoksičnost
1698 Kontinuirano liječenje
1699 Shizofrenija i funkcioniranje
1700 Nezadovoljene potrebe
1701 Antipsihotici
1702 D2 parcijalni antagonisti
1703 Farmakologija D2 parcijalnih agonista
1704 Uloga D2 parcijalnih agonista u shizofreniji
1705 D2 parcijalni agonisti i funkcioniranje
1706 Rezultati kliničkih studija i funkcioniranje
1707 Tijek bolesti
1708 Satelitski simpozij
1709 Support for patients
1710 MCCB
1711 CANTAB
1712 Patient data
1713 Non-invasive devices
1714 Data tools
1715 Clinical aids
1716 Alcohol use
1717 Support for patients
1718 Relapse prevention
1720 Pandemic. Public health
1721 Burnout
1722 Deborah Dunsire
1724 TDP-43
1725 Mild cognitive impairment
1726 Telomere
1727 Social distancing
1728 Self isolation
1730 Pandemia
1731 Estrés
1732 Cuarentena
1733 Distancamiento social
1734 Reserch
1735 Smoking
1736 Cannabis
1737 Dual diagnosis
1738 Co-morbid conditions
1739 EMA/I
1740 ACT
1741 ACT-DL
1742 Hallucinations
1743 Pandémie
1744 Quarantaine
1745 Isolation Sociale
1746 Κίνδυνος
1747 Support pour patients
1749 うつ病
1750 Télémédecine
1751 Aide pour les patients
1752 Prévention des rechutes
1753 risque
1754 Santé publique
1755 발병기전
1756 Teret
1757 Prevencija
1758 Pandemija
1759 Stres
1760 Karatena
1761 Socijalna izolacija
1762 Telemedicina
1763 Podrška pacijentima
1764 Prevencija relapsa
1767 Karantena
1771 Negovalec
1772 preprečevanje
1773 javno zdravje
1774 Odziv
1775 Ozdravitev
1776 Resnični dokazi
1777 Mehanizem delovanja
1778 Breme
1779 Družbena izolacija
1780 Podpora bolnikom
1781 Preprečevanje ponovitve bolezni
1782 Counseling
1783 Cormobidity
1784 Non-oral therapy
1785 Device-assisted therapy
1786 Advanced disease
1787 Palliative care
1788 COVID-1D
1789 Family support
1790 Prevent recurrence
1795 위험
1798 Suicide Risk
1800 Drug seeking behaviours
1801 Metabolism
1802 Counselling
1804 Mood swing
1805 Manic and depressive
1808 emotions; MDD; antidepressant; response
1810 Childhood trauma
1811 Wellbeing
1812 SHAPS
1813 EEfRT
1814 Adverse childhood experience
1815 Microbiota-gut-brain pathway
1817 Psychiatric practice
1818 Composite International Diagnostic Interview (CIDI) 3.0
1819 Bipolarity Index (BI)
1821 Metabolism
1822 Mixed features specifier
1823 CANMAT
1824 ISBD
1826 Neuronal correlates
1827 Heterogeneity
1828 Monoaminergic antidepressant
1829 Prefrontal cortex
1832 Lived-experience peer support
1833 Mobile application
1834 Mental health for all
1835 Access
1836 Investment
1837 Apps
1838 Digital peer support
1839 Pain syndromes
1840 Skin biopsy
1841 PART
1842 LATE
1843 Patient participation
1844 Brain health
1845 Patient communication
1846 Treatment trial period
1847 Addressing concerns
1848 Chronorisk
1849 Human model
1850 Chronotreatment
1851 Non-invasive monitoring
1852 Medication overuse
1853 Medication overuse headache
1854 Calcitonin gene-related protein
1855 Cortical spreading depression
1856 CSD
1857 Post-traumatic headache
1858 PTH
1859 Endorphins
1860 Enkaphalin
1861 Adrenaline
1862 epilepsy
1863 NbN
1864 Kontrola bolesti
1865 Postupanje s pacijentima
1866 Težina bolesti
1867 Personalizirano liječenje
1868 Meta-analiza
1869 Funkcija
1870 Radno mjesto
1871 Zajedničko odlučivanje
1872 Postavljanje ciljeva
1873 Alati
1874 Analiza puta
1875 Placebo efekt
1876 Ciljevi pacijenata
1877 Očekivanja pacijenata
1878 Adherencija
1879 Elderly
1880 Patients management
1881 Restore working ability
1882 Premorbid healthy state
1883 Elderly. Cognitive symptoms
1884 Communication
1886 Immune system
1887 Tauopathies
1888 Synaptic function
1889 Lysosome
1890 2 min watch
1891 Post-partum
1892 Episodic
1893 Chronicity
1894 Prophylaxis
1895 Maintenance
1896 Integrated treatment
1897 Person-centered care
1898 Psychosocial intervention
1899 Exercise
1900 Chronic disease
1901 Clinical trial design
1902 Long-acting antipsychotic
1903 Randomized trials
1904 Cognitive behavior therapy
1905 ADHD
1906 Multi-variant pattern analysis
1907 Transition
1908 History
1909 Facial expression recognition
1910 Affective cognition
1911 Emotion Recognition
1912 Microbiota–gut–brain axis
1913 Empowerment
1914 Self-care
1915 DBSA
1916 Quality of care
1917 Quality assurance
1918 Psychopathology
1919 Cancer
1920 Population study
1921 Family study
1922 Pain
1923 Micro RNA
1924 Procalcitonin
1925 CALCA
1926 Cluster headache
1927 Estrogen
1928 Gender
1929 Trigeminal neuralgia
1931 Dugodjelujući antipsihotici
1932 Njegovatelj
1933 Dijagnoza
1934 Negovalci
1935 Potek bolezni
1936 Diagnoza
1937 Upravljanje z bolniki
1938 Adherenca Upravljanje s pacienti
1939 Ponovitev bolezni
1940 Dolgodelujoči antipsihotiki za injiciranje (LAI)
1941 Upravljanje s pacienti
1942 Cilji pacientov
1943 Pričakovanja pacientov
1944 Skupno sprejemanje odločitev
1945 Delovanje
1946 Delovno mesto
1947 Okrevanje
1948 Skupno sprejemenje odločitev
1949 Postavljanje ciljev
1950 Orodja
1951 Resnost bolezni
1952 Personalizirano zdravljenje
1953 Analiza na projekcijah
1954 Placebo učinek
1955 Patient-centered therapy
1956 Goal Attainment Scale
1957 Neuroscience-based nomenclature
1958 Early-phase schizophrenia
1960 Gender differences
1961 Women's mental health
1962 Cardiovascular
1963 Immuno-metabolic
1964 Smartphone App
1965 Social dysfunction
1966 Smartphone Apps
1967 Treatment resistant depression
1968 Difficult-to-treat depression
1972 이미징
1973 아밀로이드
1974 타우
1975 Probiotic(s)
1976 Symptoms. Treatment
1977 Neuronal plasticity
1978 Trauma
1979 Oxidative stress
1980 Novel treatments
1981 Psychosocial interventions
1983 Svjetski dan mentalnog zdravlja
1984 Svjetski dan mentalnog zdravlja Lived-experience peer support
1985 Biomarkeri
1986 Samoubojstvo
1987 Svetovni dan duševnega zdravja
1988 Dostopnost
1989 Vlaganja
1990 Dobro počutje
1991 Duševno zdravje
1992 Podpora z medsebojnimi izkušnjami
1993 Telepsihiatrija
1994 Mobilna aplikacija
1995 Duševno zdravje za vse
1996 Biomarkerji
1997 Samomori
1998 Svetovni dan duševnga zdravja
1999 Obladovanje bolezni
2000 Sladkorna bolezen
2001 Kardiovaskularna bolezen
2002 Sodelovanje v oskrbi
2003 Engagement
2004 Fear
2005 Neuroscience
2006 Dijabetes
2007 Kardiovaskularne bolesti
2008 Suradnički pristup skrbi
2009 Pristup
2010 Investicija
2011 Blagostanje
2012 Mentalno zdravlje
2013 Dobrobit
2014 Stručna podrška iz životnog iskustva
2015 Telepsihijatrija
2016 Mentalno zdravlje za sve
2017 Συνοδή πάθηση
2018 Етиология
2019 Биомаркери
2020 Диагноза
2021 Социална дисфункция
2022 Приложения за смартфон
2023 Дигитално фенотипиране
2024 WMHD
2025 Expert Views
2028 마이크로바이옴
2029 면역체계
2030 미세아교세포
2031 염증
2032 Disease phenotype
2033 Atypical symptoms
2034 Immunometabolic depression
2036 CGRP antibodies
2037 Interictal burden
2038 Anxious depression
2039 Phobias
2040 Diagonsis
2041 Depression in men
2042 Depression in elderly
2044 Amoloide
2045 Amiloide
2046 Gestión de la Patología
2047 Gestión del paciente
2048 Recaída
2049 Riesgos
2050 Evolución de la enfermedad
2051 Pronóstico
2052 Tratamientos de liberación prolongada
2053 Intervenciones psicosociales
2054 Brintellix
2055 Síntomas Tratamiento
2056 Immuno-metabolic.
2057 Gestión paciente
2058 Inyectables de Liberación Prolongada
2059 Gestión Patología
2060 Disfunción Social
2061 pps
2062 Fase temprana de esquizofrenia
2063 Zgodnje odkrivanje
2064 Zgodnje zdravljenje Stigma
2065 Dolgo delujoči antipsihotiki
2066 Zgodnje zdravljenje
2067 Skrbniki
2068 Upravljanje pacientov
2069 Fizično zdravje
2070 Zdravljanje
2071 Farmakologije
2072 Profilaksa
2073 Ohranjanje
2074 Rezistenca na zdravljenje
2075 Nezadovoljiv odgovor
2076 Klinična raziskava
2077 Genetika
2078 Patologija
2079 Postupanje s pacientima
2080 Tjelesno zdravlje
2081 Farmakologija
2082 First epizode
2083 Rano otkrivanje
2084 Rana intervencija
2085 Dizajn kliničkog ispitivanja
2086 Adherenca
2087 Napoved bolezni
2088 Functional communication
2089 Cognitive decline
2090 Evaluación
2091 Cefalea en racimo
2092 Estrógeno
2093 Género
2094 Cormorbilidad
2095 cnssypsium2020
2096 Forgetfulness
2097 Normal aging
2098 Teleneurology
2099 Migraña
2100 Chronic medical illness
2101 Lack of motivation
2102 Pseudodementia
2103 Chronic migraine
2104 Barrier to care
2105 Computed tomography
2106 Magnetic resonance imaging
2107 TIA
2108 Thunderclap headache
2109 Healthy eating plate
2110 Migraine preventive eligibility
2111 Evidence
2112 Clinical trial endpoint
2113 Co-primary endpoints
2114 Most bothersome symptom
2115 PACAP-38
2116 Hypothalamus
2117 Cephalgia
2118 Trigeminocervical
2119 Diagosis
2120 Mediator
2121 T cells
2122 Macrophages
2123 Trigeminal nerve
2124 Neural pathways
2125 Central nervous system
2126 Breastfeeding
2127 Elderly
2128 CGRP monoclonal antibody
2129 Gepant
2130 Dyskinesia
2131 Falls
2132 DMT
2133 Telenursing
2134 LRRK2
2135 Astrocytes
2136 Immune response
2137 Resistance training
2138 Integrated care model
2139 Interdisciplinary
2140 Rehabilitation
2141 REM sleep behavior disorder
2142 α-synucleinopathy
2143 GBA1
2144 SNAC
2145 Neurodegeneration
2146 Antibody
2147 Smartphone
2148 Sensors
2149 Cognitivo
2150 Riesgo
2151 Conception
2152 Teratogenicity
2153 Postpartum
2154 ICDH-3
2155 Menopause
2156 HRT
2157 Perimenopause
2158 Postmenopause
2159 Wear-off
2160 Raziskava
2161 Razlike med spoloma
2162 Mentalno zdravje žensk
2163 Obvladovanje bolezni Zdravljenje
2164 Strojno učenje
2165 Podatki velikega obsega
2166 Aplikacije za pametne telefone
2167 Etiologija
2168 Socialna disfunkcija
2169 Digitalno fenotipiziranje
2171 Metabolismo
2172 Inflamación
2173 Obesidad
2174 Fisiopatología
2175 Psychiatry Connect
2176 Meeting series
2177 webinar
2178 Australia
2179 Webinar series
2180 Zgodnja faza shizofrenije
2181 PRELAPSE Study
2182 Correll
2184 Long-acting injectable antipsychotics; Schizophrenia; Healthcare utilization; Healthcare cost
2188 Conference
2189 injection à action prolongée
2190 Congrès
2191 Oestrogen
2202 Vaccine
2203 D2 receptor partial agonists
2204 Patient life engagement
2207 Psychiatry Connect; 2021 Meeting Series
2208 D2 receptor partial agonists
2209 Patient life engagement
2210 Melancholia
2211 Brain volume
2212 Adjunctive therapy
2213 Metabolic side effects
2214 Early onset schizophrenia
2216 Psychiatry Connect 2021 Meeting Series
2217 Psychiatry Connect 2021 Meeting Series; recap; PRELAPSE; 2021
2218 Recap
2219 PRELAPSE
2220 Maintenance treatment
2221 Serotonin
2222 GWAS
2223 Dopamine partial agonists
2225 Ultra-high-risk
2226 Early intervention services
2227 Long-acting injectable
2228 Clinical outcome
2229 Immunometabolic
2231 Neuroplasticity
2232 Family intervention
2233 Family therapy
2234 Nonadherence
2235 Global mental health
2236 Inclusiveness
2237 Human rights
2238 Equity
2239 Collectiveness
2240 Language
2241 Air pollution
2242 Beta-amyloid
2244 수면
2245 운동
2246 낙상
2247 식단
2248 Föreläsning från Insikt Psykiatri 2020
2249 Episode
2250 Patient-reported outcome measures
2251 Training & education
2252 Genomics
2254 Shared decision making
2255 Migraine burden
2256 Migraine-related disability
2258 위험 요인
2259 위험 요소
2261 Epigenetic
2262 Methylation
2263 ZBTB16
2264 Cerebral organoids
2265 Agonista parcial del receptor D2
2266 Compromiso del paciente
2267 Terapia
2268 Fenotipo de la enfermedad
2269 Síntomas atípicos
2270 Depresión Inmunometabólica
2271 Heterogeneidad
2272 Resistencia al tratamiento
2273 Efectos secundarios metabólicos
2274 Metacognición
2275 Realidad virtual
2276 Síntomas positivos
2277 Anticuerpo monoclonal CGRP
2278 Embarazo
2279 Lactancia
2280 Posparto
2281 Menopausia
2282 Perimenopausia
2283 Postmenopausia
2284 Estrógenos
2285 Φυσική υγεία
2286 Λειτουργικό αποτέλεσμα
2287 Reliability
2288 Healthcare professional
2289 Future of psychiatry
2290 Audit
2291 Sex
2292 Race
2293 Disparity
2294 Chronic
2295 Affective
2296 Metabolic abnormalities
2297 Vascular dementia
2298 Plasma biomarkers
2299 P-tau
2300 Mitochondrial dysfunction
2301 P53
2302 Non-adherence
2303 Suboptimal adherence
2304 Atypical antipsychotic
2305 Recurrence
2306 Cardiovasular disease
2307 Psychosocial function
2308 Remisión
2309 Embotamiento Emocional
2310 Anxiety Disorder
2311 Primary care
2312 Behavioral changes
2313 Emotional Changes
2314 Long-term function
2315 Clinical high risk
2316 불안 우울증
2317 #recap #PsychiatryConnectRecap
2318 Meeting
2319 Psychiatry Connect Recap
2320 유전체학
2322 Stages of grief
2323 Case Report
2324 저항 운동
2325 Dermatological
2326 Reward processing
2327 Individualized treatment
2328 Metabolic risk
2329 Lewy Body dementia
2330 Treatment-resistant depression
2331 Neurological soft signs
2332 Reward
2333 Turn-taking anomalies
2334 Speech
2335 Precision psychiatry
2336 Tumor necrosis factor alpha
2337 Microglial activation
2338 Translocator protein
2339 Prostaglandin E2
2340 Persistent
2342 Population
2343 Covid19
2344 BDNF
2345 Smartphones
2346 Research. Screening
2347 Lifestyle intervention
2348 Type 2 diabetes
2349 Community care
2350 COH-FIT
2351 Coronavirus
2352 Geriatric psychiatry
2353 Health Inequalities
2354 Family risk
2355 Headspace
2357 Diagnostic criteria
2358 Patient voices
2359 Emotional health. Quality of life
2360 Cognitive function
2361 Disease burden
2362 정서적 둔마
2363 무쾌감증(anhedonia)
2364 외상
2365 Course of diseas
2366 e Diagnosis
2367 Preventive treatments
2368 CGRP switching
2369 Acute symptoms
2370 Patient-reported outcomes
2371 Study
2372 Acute attack
2373 Patient preferences
2374 Electroencephalography
2375 Disease impact
2376 Impact
2377 Insights
2378 Κατάθλιψη
2379 Ψυχική Υγεία
2380 FINGER
2381 Structural MRI
2382 Pharmacoeconomic
2383 Number needed to treat
2384 Romance
2385 Sexuality
2386 Loneliness
2387 Love
2388 E-health
2389 E-mentalhealth
2390 DIALOG+
2391 Solution-based
2392 Long COVID
2393 Psychological trauma
2394 Treatment gaps
2395 Healthcare access
2396 MOH
2397 Medication-overuse headache
2398 CaMEO study
2399 Schizophrenia; LAI;
2400 COVID-19 vaccines
2401 Sex differences
2402 Hormonal differences
2403 CGRP receptor
2404 Physical healt
2405 Infection
2406 World Suicide Prevention Day
2407 Digital
2408 Future
2409 Disorders of gut-brain interaction
2410 Treatment gap
2411 ICHD3
2412 SNOOP
2413 PIN
2414 Abuse
2415 Photophobia
2416 Hyperacusis
2417 Allodynia
2418 Barriers
2419 Preventive therapy
2420 Withdrawal
2421 Neurofibrillary tangles
2422 Phosphorylated tau
2423 Diagnostic process
2424 Multidisciplinary team
2425 MDT
2426 Socioeconomic status
2427 Anti-CGRP monoclonal antibody
2428 Treatment discontinuation
2429 Side effects
2430 Myelin
2431 White matter
2432 Neuron
2433 Interleukins
2434 NRXN1
2435 Neurexin
2436 Chronic trajectory
2437 Basic science
2438 Progression
2439 Remodeling
2440 Defensa
2441 Cefalea
2442 Carga de la migraña
2447 Aislamiento social
2448 Curso de la patología
2449 Estrés Oxidativo
2450 Ψύχωση
2451 Επιδημιολογία
2452 원격의료
2453 정신의학의 미래
2454 5HT3
2455 psychiatrie
2456 maladie psychiatrique
2457 modèles animaux
2458 SOBP
2461 Equidad
2462 Calidad de la atención
2463 Futuro de la psiquiatria
2464 Demencia con cuerpos de Lewy
2465 Trauma infantil
2466 Experiencia adversa infantil
2467 Comportamiento
2468 Función a largo plazo
2469 Alto riesgo clínico
2470 Persistente
2471 Riesgo muy alto
2472 Rehabilitación cognitiva
2473 Volumen cerebral
2474 Grupo de alto riesgo
2475 Pródromo
2477 Demencia vascular
2479 Na nevroznanosti temelječa nomenklatura (NbN)
2480 Zdravljenje osredotočeno na bolnike
2481 Lestvica doseganja ciljev
2482 Predklinično
2483 Raziskovanje
2484 Sindrom oslabljene (atenuirane) psihoze (APS)
2485 Sinaptično redčenje
2486 Hipokampus
2487 Prodrom
2488 Nezadosten odziv
2489 Podtipi
2490 Heterogenost bolezni
2491 Terapevtsko spremljanje zdravil
2492 Življenjski cilji
2493 Stroški
2494 Nadzor bolezni
2495 Bolnikovi cilji
2496 Shizofrenija
2497 대기오염
2532 공중보건
2533 대유행
2535 원격 의료
2536 전화상담
2537 만성 코로나
2538 심리적 외상
2541 Sueño
2542 Tumor
2543 Necrosis
2544 Proteína
2546 Epigenética
2547 Medicina personalizada
2548 Trauma Psicológico
2549 Epidemología
2550 Psiquiatría geriátrica
2551 Amiloidea
2552 PET de amiloide
2553 Contaminación atmosférica
2554 Disease-modifying drug (DMD)
2561 Τεχνολογία
2563 Mobile app
2564 Body mass index (BMI)
2566 Disease awareness
2567 Messaging
2568 PCR test
2569 Trigeminal
2570 Lockdown
2571 Switching
2572 MIDAS HIT-6
2578 Real-world studies
2579 Assessment tools
2581 Digital medicine
2582 Early assessment
2584 Memory
2586 Life engagement
2587 Gene therapy
2588 Migraine
2589 Early in life adversities
2590 Adverse childhood experiences
2591 기능적 결과
2593 Patient-reported outcomes
2594 webinaari
2595 ajokyky
2596 psykiatriset sairaudet
2597 Korkeila
2598 Huuskonen
2599 Detoxification
2600 Treatment risk assessment
2601 Patient partnership
2602 Preventing hospitalization
2604 学会共催セミナー
2605 Migraine without aura
2607 COVID-19 pandemic
2608 オンデマンド動画
2609 セミナー・シンポジウム
2611 Citocinas
2612 Disregulación de citocinas
2613 Citocinas proinflamatorias
2614 Poligénicos
2615 Puntuación de riesgo
2616 Enfermedad Bipolar
2617 Imagen mental
2618 Estructura cerebral
2619 Polaridad
2620 desarrollo de fármacos
2621 Anomalías metabólicas
2622 L-acetilcarnitina
2623 Melancolia
2624 TDM melancólico
2625 inmunoterapia
2626 Diseminación cerebral
2627 Childhood adversity
2628 Maladaptive family function
2631 Accuracy
2632 Multimodal
2633 Brain structure
2634 Functional connectivity
2635 Personalised medicine
2655 Economic cost
2656 E-mental health
2657 Migraine prevelance
2658 Omics
2659 Proteomics
2660 Suicide prevention
2661 technologie
2662 Memoria
2663 Terapia de genes
2664 Diagnose
2666 antipsychotiques
2667 symposium satéllite
2668 lieu de travail
2669 Disease-Management
2670 Erstepisode
2671 Adhesion
2672 journée mondiale de la santé mentale
2673 Beurteilung
2674 Behandlung
2675 Symptome
2676 Unzureichendes Ansprechen
2677 Patientenmanagement
2678 LQ
2679 Forschung
2680 Risiken
2681 Erkrankungsverlauf
2682 Ätiologie
2683 Komorbidität
2684 Therapieresistenz
2685 Kognition
2686 Belastung
2687 Prävention
2688 Stigmatisierung
2689 Psychosen
2690 prise en charge précoce
2691 Pharmakologie
2692 Gestion des maladies
2693 Gestion des patients
2694 Insufficient response
2695 Therapy Resistance
2696 Load
2697 Stigmatization
2700 wird bearbeitet
2701 während der Krankheit
2702 Krankheitsmanagement
2703 Funktion
2704 Erkenntnis
2705 Patientenversorgung
2706 Auswertung
2707 Daten aus der realen Welt
2708 Wirksamkeit
2709 Leistung am Arbeitsplatz
2710 funktional Erholung
2711 Antipsychotika
2712 Ziele des Patienten
2713 körperliche Gesundheit
2714 Herzkreislauferkrankung
2715 Risikofaktor
2716 Gewichtszunahme
2717 Nebeneffekt
2718 Stoffwechselkrankheit
2719 la prise en charge de la maladie
2720 prise en charge du patient
2721 symptômes
2722 traitement
2723 abus médicamenteux
2725 Muistisairaus
2726 Psykiatriaa
2727 Geriatria
2728 Alzheimerintauti
2729 Uni
2730 Työuupumus
2731 Masennus
2732 No-adherencia
2733 estudios reales
2734 herramientas de evaluación
2735 Repsuesta inadecuada
2736 Compromiso de vida
2737 Sleep disorders
2738 Cortisol
2739 Cognitive Enhancers
2740 BDNF-TrkB signaling
2741 Neural network
2742 Monoaminergic
2743 Glutaminergic
2744 GABAergic
2745 Neurotransmission
2747 Engram
2748 Fear memory
2749 Thalamus
2750 Phenotype inflammation
2752 Recommendations
2753 Japan
2755 ECNP 2021; Affektive Störungen; Schizophrenie
2756 ECNP 2021; troubles affectifs; schizophrénie
2757 päänsärky
2758 migreeni
2759 psykiatrisen hoidon historia
2760 lääkehoito
2761 skitsofrenia
2762 psykiatria
2763 psykoosi
2764 Hoitomyöntyvyys
2765 Hoitoon sitoutuminen
2768 FinnGen
2769 Relapsi
2770 Ofer Agid
2771 Mielenterveys
2772 Avatar
2773 Lapsuuden trauma
2774 Psykiatrinen häiriö
2775 Depressio
2776 Lääketieteellinen päätöksenteko
2777 Diagnostiikka
2778 Psykitria
2779 Aivot
2780 Kliininen arviointi
2781 Epidemija
2782 Bolniki
2783 Ελλιπής απάντηση
2784 Ulcerative colitis
2785 Sitgma
2786 Opening Minds
2787 Mental health services
2788 Psykoterapia
2789 Gray matter
2790 Temporal lobe
2791 Second-generation antipsychotic
2792 First-generation antipsychotic
2794 Meninges
2795 Blood-brain barrier
2796 Σχιζοφρένεια
2797 Psychosis Agitation
2798 Vaccine
2799 Transport vehicle
2800 Chimerical molecules
2801 OGA inhibitors
2802 Synuclein
2803 Glial activation
2804 Ethnicity
2805 Cognitively unimpaired
2806 Latin America
2807 Africa
2808 Europe
2809 au cours de la maladie
2810 Loss of pleasure
2811 Social Anhedonia
2812 Caregiver burden
2813 Hyperglycemia
2814 JAMA
2815 メンタルヘルス、抑うつ、不安障害
2816 メンタルヘルス
2817 抑うつ
2818 不安障害
2819 自殺
2820 BMJ
2821 不安
2822 心的外傷後ストレス障害
2823 Lancet
2824 大うつ病性障害
2826 salud publica
2827 Coste económico
2828 Symptom control
2829 WMHD
2830 Psicosis temprana
2831 Circuitos cerebrales
2832 Salud del cerebro
2833 Red neuronal
2834 Monoaminérgico
2835 Glutaminérgico
2836 Neurotransmisión
2839 統合失調症
2840 双極性障害
2841 モバイルヘルス
2843 COVID-19後遺症
2844 認知機能障害
2845 悲嘆
2846 グリーフ
2847 ICU
2848 スティグマ
2849 リアルワールドデータ
2850 RWD
2853 Social Behavior
2854 Sozialverhalten
2855 Music
2856 Music Therapy
2857 孤独感
2858 メタ解析
2860 Phopho-tau
2861 Precision
2862 Aβ42
2863 Well-being
2864 ウェルビーイング
2865 睡眠障害
2866 自傷
2867 弁証法的行動療法
2868 DBT
2869 Probabilistic model
2870 Deterministic model
2871 Environmental exposures
2872 ApoE ε4
2873 バイオマーカー
2874 逆境
2875 若年期の逆境
2876 トラウマ
2877 若年期のトラウマ
2878 aivoterveys
2879 neurologiset oireet
2881 Neurobiologiaa
2882 Cortical thinning
2883 Index
2884 Vulnerability
2885 Aging brain
2886 Functional
2887 Sex differences
2889 Early phase
2890 Women
2891 Affective symptoms
2892 Mood disorder
2893 全般不安症
2894 GAD
2895 制限性食物摂取症
2896 RCT
2897 パニック障害
2898 ネットワークメタ解析
2899 jornada
2900 Sustancias
2901 Trastorno por consumo de sustancias
2902 Experiencia traumática
2903 暴力的行動
2904 中核的信念
2905 core belief
2906 Uskomus
2907 Tiede
2908 Tutkimustieto
2909 Oikeellisuus
2910 Long-term outcomes
2911 慢性疼痛
2912 アクセプタンス&コミットメントセラピー
2913 認知行動療法
2914 疾病管理
2915 患者管理
2916 予防
2917 治療
2918 公衆衛生
2919 遠隔医療
2920 IL-18
2921 Precursor
2922 Suspiciousness
2923 UKバイオバンク
2924 脳画像
2925 嗅覚
2926 認知機能
2927 Patient-based assessment
2928 Treatment efficacy
2931 家族焦点化療法
2932 思春期
2933 身体活動量
2934 NICU
2935 小児
2936 精神疾患
2937 自閉者
2938 母親
2939 産後うつ
2940 音声分析
2941 性的マイノリティ
2942 医療従事者
2943 遠隔精神医療
2944 救急医療
2945 周産期
2946 非医療従事者
2947 気温
2948 小学生
2949 精神神経症状
2950 SARS
2951 MERS
2952 パーキンソン病
2953 肥満
2954 若年期
2955 ヨガ
2956 気分調節
2957 メンタルヘルスケア
2958 青少年
2959 心理的苦痛
2960 妊婦
2961 産後女性
2962 精神障害
2963 多遺伝子リスクスコア
2964 PRS
2965 心血管疾患
2966 統合失調症スペクトラム障害
2967 孤独
2968 救急医
2969 ネットワークメタアナリシス
2970 燃え尽き症候群
2971 レジリエンス
2972 高齢者
2973 アルツハイマー病
2974 repetitive negative thinking
2975 乳幼児期
2976 睡眠
2977 境界性パーソナリティ障害
2978 BDP
2979 末梢動脈疾患
2980 PAD
2981 PHQ-8
2982 EQ-5D VAS
2983 QQL
2984 不妊治療
2985 急性ストレス反応
2986 遠隔心理診療
2987 若年者
2988 夜間人工光
2989 ALAN
2990 気分障害
2991 全般性不安障害
2992 強迫性障害
2993 機能的磁気共鳴画像法
2994 経済的苦境
2995 WSAS
2996 GAD-7
2997 精神的健康
2998 重度精神疾患
2999 SMI
3000 少数民族
3001 小児がん
3002 大学生
3003 医師
3004 自殺念慮
3005 妊娠悪阻
3006 生活習慣
3007 経済的な悪影響
3008 不安病状
3009 周産期女性
3010 雇用
3011 行動障害
3012 心筋梗塞
3013 死亡リスク
3014 メディア
3015 認知機能リハビリテーション
3016 DNAメチル化データ
3017 抗うつ薬
3018 再発リスク
3019 高所得国
3020 身体疾患
3021 早産時
3022 父親
3023 認知症
3024 高齢
3025 ワクチン
3026 自殺未遂
3027 救急科
3028 社会不安障害
3029 インターネット認知行動療法
3030 費用対効果
3031 メンタルヘルス不調
3032 心不全
3033 不眠症
3034 神経疾患
3035 精神科診療
3036 日本
3037 児童福祉制度
3038 後遺症
3039 精神的苦痛
3040 注意欠如・多動症
3041 小児期
3042 中高年
3043 電話介入
3044 在宅勤務
3045 身体的・精神的ウェルビーイング
3046 CES-D
3047 CD-RISC10
3048 精神科遠隔診療
3049 虐待
3050 女性
3051 BPD
3052 Disease modification
3054 graue Substanz
3055 matière grise
3056 Poor memory
3057 Panic Disorder
3058 急性呼吸窮迫症候群
3059 ARDS
3060 外傷後ストレス障害
3062 メンタルヘルスサービス
3063 Ansiedad
3064 Cuadro clínico depresión y ansiedad
3065 Respuesta al tratamiento
3066 Vortioxetina
3067 Estudio Reconnect
3068 物質使用
3070 非臨床
3071 リスク
3072 ストレス
3073 薬理
3074 回復
3075 アンへドニア
3077 Long acting therapy
3078 Long acting antipsychotic
3079 ガイドライン
3080 日本うつ病学会
3081 炎症
3082 Long-term outcome
3083 核磁気共鳴画像
3084 脳ワイド関連解析
3085 BWAS
3086 brain-wide association studies
3087 ゲノムワイド関連分析
3088 Ischemic heart disease
3089 Systemic syndrome
3091 Treatment strategies
3092 Behavioral interventions
3093 Brain structure and function
3094 Inequality
3095 Underserved patient populations
3096 Bias
3097 Race and ethnicity
3098 Emergency treatment
3099 Treatment trends
3100 Acute treatment
3101 Treatment guidelines
3103 sistema nervioso central
3104 双極性障害I型
3105 Mobile health
3106 Prevalence
3107 Physiotherapy
3108 Speech and language therapy
3109 Mindfulness-based interventions
3110 Occupational therapy
3111 Real-life functioning
3112 Neural networks
3113 Augmented intelligence
3114 Deep learning
3116 Digital navigator
3117 Asynchronous telehealth
3118 Telehealth
3119 Digital clinic
3120 Social determinants
3121 Functionality
3122 Social processing
3123 Emotion regulation
3124 Mentalizing
3125 Life satisfaction
3126 Multiple sclerosis
3127 Parkinson’s disease
3128 South America
3129 Patient-centric
3130 遺伝子
3131 ultra-rare coding variants
3132 Pisa syndrome
3133 Tailored therapy
3134 Patient views
3136 Endocannabinoids
3137 Exosomes
3138 mRNA translation
3139 Electronic wearable devices
3140 Salience network
3141 Joint decision-making
3142 Treatment outcomes
3143 BrainChart
3144 脳の発達
3181 Emotional processing
3183 Anti-inflammatory cytokines
3184 Pro-inflammatory cytokines
3193 Chronification
3194 Tailored treatment
3195 Migraine triggers
3198 日本人
3199 突然変異
3200
3201 ニューロン
3204 Digital biomarkers
3206 Migraine disability
3207 Patient burden
3208 Treating the whole patient
3209 Measuring disease
3211 Disease mechanisms
3212 Future research
3213 a-synuclein
3214 REM sleep behaviour disorder
3215 Disease-modifying therapies
3216 Family life
3217 Work life
3218 Riscos
3219 Psicose
3220 Low mood
3221 Low interest
3222 Daily functioning
3223 Patient compliance
3224 Ansiedade
3225 Medo
3226 Neurociência
3227 診断
3228 鑑別診断
3229 精神科受療
3230 救急患者
3231 Cardiometabolic risk factors
3232 Hypertension
3233 Physical inactivity
3235 Frontotemporal dementia
3236 Neuropsychological testing
3239 Healthcare resource utilization
3240 Preventive treatment
3241 Economic burden
3243 Cognitive training
3244 Psychosocial rehabilitation
3246 N-methyl-D-aspartate (NMDA) receptor
3247 Positive and Negative Syndrome Scale (PANSS)
3249 SCHEMA
3250 Osteopontin
3251 Predominant negative symptoms
3252 TRANSD
3253 Personalized management
3254 Functional remission
3255 Digital platform
3259 非器質性精神病
CSV
Progress in Mind次のウェブサイトに移動します
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
このサイトの情報は、医療関係者のみを対象に提供されています。
Congress
Register for access to Progress in Mind in your country